Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven Johnson, Rodger D. MacArthur, Mark Miller, William T. Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, Lori Van Meter (+4 others)
2004 Critical Care Medicine  
doi:10.1097/01.ccm.0000145229.59014.6c fatcat:rfc6lrdxfvcqfhb3efn7ei2pvu